Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Hiroko Masamune"'
A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia
Autor:
Jin Zhou, Brian Lian, Hiroko Masamune, Paul M. Yen, Lauren R Waskowicz, Xiao Hui Liao, Samuel Refetoff, Andrea Lim, Brian Tran, Dwight D. Koeberl
Publikováno v:
Thyroid
Background: Glycogen storage disease type Ia (GSD Ia), also known as von Gierke disease, is the most common glycogen storage disorder. It is caused by the deficiency of glucose-6-phosphatase, the enzyme that catalyzes the final step of gluconeogenesi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56c1c0dd529474fbd7b60a56247af2db
https://europepmc.org/articles/PMC6707038/
https://europepmc.org/articles/PMC6707038/
Autor:
Joel Neutel, Hiroko Masamune, Marianne Mancini, Rizwana Mohseni, Brian Lian, Michael Dao, Rohit Loomba, Randall Severance, Carmen Margaritescu, Satinder Saini, David Bernard, Ken Homer, Brian Tran
Publikováno v:
Journal of Hepatology. 70:e150-e151
Publikováno v:
The Chemical Record. 13:257-264
Note from the Editor: It is with great pleasure and enthusiasm that I introduce this essay which accompanies the publication of the fourth segment of the Tetsuo Nozoe Autograph Books. In the conceptualization stages of this project—which shall appe
Publikováno v:
Cardiovascular Research. 40:138-145
Objective: The aim of this study was to characterize the adenosine A3 receptor agonist, N 6-(3-chlorobenzyl)-5′- N -methylcarboxamidoadenosine (CB-MECA), evaluate its ability to reduce myocardial ischemia/reperfusion injury and determine the role o
Publikováno v:
Chemical record (New York, N.Y.). 13(2)
Autor:
John P. Umland, Anthony Marfat, James F. Eggier, Sally C. Marshall, J.T. Shirley, Enrique Vazquez, Kelvin Cooper, Jeanene E. Tickner, Hiroko Masamune, John B. Cheng
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 5:1965-1968
The synthesis and the in vitro properties of a novel series of potent and selective phosphodiesterase type IV (PDE IV) inhibitors is described. Despite bearing structural similarity to rolipram, several of these compounds have much reduced affinity f
Autor:
Kelvin Cooper, Anthony Marfat, Jeenene E. Tickner, James F. Eggler, Hiroko Masamune, Allen J. Duplantier, Sally C. Marshall, John B. Cheng, Kenneth G. Kraus, John P. Umland, J.T. Shirley
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 5:1969-1972
The synthesis and biological properties of a novel series of potent and selective phosphodiesterase type IV (PDE IV) inhibitors are described. These catechol benzimidazoles were designed from rolipram and initial compounds reflected a similarly high
Autor:
Lawrence S. Melvin, Jeanene E. Tickner, John B. Cheng, J.T. Shirley, Frank W. Rusek, Anthony Marfat, James F. Eggler, Hiroko Masamune
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 5:1371-1376
A series of pyridine chromanols were synthesized and evaluated as LTD 4 -antagonists (LTD 4 -A). The quinoline sidechain of this class of such agents, as exemplified by REV-5901, has until now been deemed as essential for potent activity. However, by
Autor:
A. Marfat, J. W. Watson, Kelvin Cooper, David B. Damon, James F. Eggler, Lawrence S. Melvin, Hiroko Masamune, John B. Cheng, J. Delehunt, R. J. Chambers
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 5:1377-1382
The combination of key structural pharmacophores found in known leukotriene D4 (LTD4) receptor antagonists with those of potent platelet activating factor (PAF) receptor antagonist UK-74,505 has led to the synthesis of hybrid compounds CP-96,021 and
Autor:
G.W. Antognoli, J.T. Shirley, A. Marfat, C.F. Wright, Thomas J. Carty, Frank W. Rusek, J. W. Watson, J. Delehunt, B. A. Naclerio, James F. Eggler, J.S. Pillar, Herbert Sherman, E.G. Andrews, Francis J. Sweeney, K. W. Freiert, R. Breslow, C. J. Mularski, V. L. Cohan, C J Pazoles, Lawrence S. Melvin, L.A. Rappach, John B. Cheng, David B. Damon, Jeanene E. Tickner, Judith L. Collins, P. Reiche, Hiroko Masamune, M. P. Carta, James D. Eskra, Hada William Andrew, R. J. Chambers
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 5:1365-1370
The development of two novel LTD 4 receptor antagonists as clinical candidates for the treatment of asthma is described. The first generation compound, CP-80,798, was found to be a balanced 5-lipoxygenase inhibitor (5-LOI)/LTD 4 antagonist (LTD 4 -A)